Search Results - "van der Zande, K."

Combined Cabazitaxel and Carboplatin Treatment of Metastatic Castration Resistant Prostate Cancer Patients, With Innate or Acquired Resistance to Cabazitaxel Monotherapy by van der Zande, K., Tutuhatunewa-Louhanepessy, R.D., Hamberg, P., Ras, S., de Feijter, J.M., Dezentjé, V.O., Broeks, A., Cornelissen, S., Beeker, A., van der Noort, V., Zwart, W., Bergman, A.M.

“…•Innate or acquired resistance to cabazitaxel in mCRPC patients is a common event.•Addition of carboplatin in these cases, results in a secondary…”
Get full text

1818P Final results from a randomized phase II study of cabazitaxel (CBZ) versus an androgen receptor targeted agent (ARTA) in patients with poor-prognosis castration-resistant prostate cancer (mCRPC) by van der Zande, K., van der Noort, V., Busard, M., Hamberg, P., Ras - van Spijk, S., de Feijter, J., Dezentje, V., Tascilar, M., Houtsma, D., Beeker, A., van den Berg, P., ten Oever, D., Oving, I.M., Zwart, W., Bergman, A.M.

Get full text